Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Premature labour Age: Adult Condition: Step 1: Initial bolus |
Dose: Intravenous – 0.9 ml (6.75 mg) Frequency: once Duration: over 1 minute Note: Total duration of treatment should not exceed 48 hours. Maximum total dose: 330.75 mg. |
|
Indication: Premature labour Age: Adult Condition: Step 2: Loading infusion |
Dose: Intravenous – 24 ml/hour (18 mg/hour) Frequency: continuous Duration: 3 hours Note: Total duration of treatment should not exceed 48 hours. Maximum total dose: 330.75 mg. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: Tablet – No approved pediatric dosage available Note: Not recommended |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Delay of imminent preterm birth Condition: Renal impairment |
Dose: Injection – There is no experience with atosiban treatment in patients with impaired function of the kidneys Note: Renal impairment is not likely to warrant a dose adjustment since only a small extent of atosiban is excreted in the urine |
Administration
- Must be administered by healthcare professionals
- Given as IV infusion
Side Effect
- Nausea
- vomiting
- headache
- dizziness
- flushes
- tachycardia
- hypotension
- hyperglycaemia
- Injection site reactions
- insomnia
- pruritus
- rash
- pyrexia
- Rarely
- uterine haemorrhage and atony
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Other tocolytic drugs (e.g. Ca channel blockers, betamimetics)
|
Increased risk of pulmonary oedema
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Premature Membrane Rupture >30 Weeks
|
Risk to fetal health
|
|
Intrauterine Growth Problems
|
Can worsen fetal condition
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store in a refrigerator (2°C-8°C). Keep away from light & moisture. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.